Protocol
Omega-3 fatty acid supplementation
Fish oil · EPA/DHA · Marine n-3 fatty acids · Omega-3 index · Icosapent ethyl (prescription EPA)
Human RCT evidence exists but is genuinely contested, and none of it measures lifespan or healthspan. VITAL randomised over 25,000 adults to 1 g/day marine n-3 and found no reduction in major cardiovascular events (HR 0.92) and no reduction in cancer (HR 1.03); the authors concluded supplementation did not lower incidence of either. STRENGTH, in 13,000+ statin-treated high-risk patients with high triglycerides and low HDL, found no difference versus corn oil (12.0% vs 12.2%, HR 0.99). REDUCE-IT is the main positive trial, but it tested prescription icosapent ethyl (high-dose purified EPA), not ordinary fish oil, in statin-treated patients with elevated triglycerides, cutting the primary endpoint from 22.0% to 17.2% (HR 0.75); its mineral-oil comparator remains debated. So: for a general, well-nourished population taking over-the-counter fish oil, the best evidence is null. For a specific high-risk, high-triglyceride, statin-treated subgroup, a specific prescription drug showed benefit. What is NOT shown: any effect on mortality-as-longevity, biological ageing markers, or healthspan endpoints. Observational associations between higher blood omega-3 and life expectancy (cited by Everlab) are not causal and should not be presented as trial evidence. Two caveats on this profile: the TGA website was unreachable across repeated fetch attempts this session, so the Australian regulatory field is returned null rather than guessed; and Melbourne Functional Medicine's blog returned HTTP 403, so its omega-3 recommendation could not be verified and it is excluded from the clinic list. Advantage Medical Group (Singapore) does recommend omega-3s on its own site, but it is not in the supplied SG clinic universe, so it is likewise excluded from offeredBy.
At a glance
- Evidence
- Clinical
- Singapore (HSA)
- Not a registered therapeutic product. Fish oil / omega-3 is regulated by HSA as a health supplement, which requires no pre-market approval or licensing; dealers self-assess compliance with HSA safety, quality and labelling requirements and may notify HSA voluntarily. Legally sold and freely available, but it may not be labelled, advertised or promoted for any specific medicinal purpose, or claimed to treat or prevent disease.
- Australia (TGA)
- No TGA position on file
- Offered at
- 1 clinic
Singapore
Health Sciences Authority
- HSA status
- Not a registered therapeutic product. Fish oil / omega-3 is regulated by HSA as a health supplement, which requires no pre-market approval or licensing; dealers self-assess compliance with HSA safety, quality and labelling requirements and may notify HSA voluntarily. Legally sold and freely available, but it may not be labelled, advertised or promoted for any specific medicinal purpose, or claimed to treat or prevent disease.
- In our SG set
- Tracked in Singapore
- SG clinics
- None on file
Australia
Therapeutic Goods Administration
- TGA status
- No position on file
- In our AU set
- Tracked in Australia
- AU clinics
- 1
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.
What it is
Plain-language explainer
Omega-3 fatty acid supplementation means taking the long-chain marine fats EPA and DHA, usually as fish oil capsules, and sometimes tracking blood levels via the "omega-3 index". In longevity clinics it is offered as a low-cost base supplement, typically framed around cardiovascular risk, inflammation and cognition. A separate prescription-strength purified EPA product (icosapent ethyl) exists and should not be conflated with over-the-counter fish oil.
Categories
Protocol
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Regulatory overview of health supplements · Health Sciences Authority (HSA), Singapore
- Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL) · New England Journal of Medicine via PubMed
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT) · New England Journal of Medicine via PubMed
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events (STRENGTH) · JAMA via PubMed
- 10 Best Longevity Supplements · Everlab (Australia)
- Supplements and longevity: a measured, evidence-based approach · Advantage Medical Group (Singapore)
Every entity profile on variis is sourced. Not medical advice.